Anticancer agents based on prevention of protein prenylation
CA 2353867 C · Owner: Okolotowicz, Karl J. · Inventors: Lefler, Scott R.; Okolotowicz, Karl J.; Robinson, Dale E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Prenylating enzymes are involved in modifying oncoproteins such as RAS, so , that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. .alpha.-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 9, 1999 and granted October 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 9, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 9, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.